Search Results

Displaying: 25 / 100 / 200 results

Ordered by: Date (newest first) / Date (oldest first)

Death of a reagent

22 August 2014 In the Pipeline

Fashion and progress combine to mean some reactions and reagents persist, while others fall by the wayside, says Derek Lowe

The crystal ball that can tell lies

29 July 2014 In the Pipeline

X-ray structures are not necessarily definitive, says Derek Lowe, especially when it comes to biomolecules

Too big to innovate?

25 June 2014 In the Pipeline

How strong is the correlation between company size and research productivity, asks Derek Lowe

Messy megamergers

29 May 2014 In the Pipeline

Big company buyouts are more about immediate gains and rarely consider the impact on research, says Derek Lowe

Engineering serendipity

25 April 2014 In the Pipeline

It takes more than random stumbling to find new reactions, says Derek Lowe

Known unknowns

27 March 2014 In the Pipeline

New molecules with unpredictable biological activity deserve sensible amounts of respect, says Derek Lowe

Tools of the trade

24 February 2014 In the Pipeline

Derek Lowe wonders what the most life-changing instrument for organic chemists is, and what might be missing from the toolbox

Beelzebub Pharma Ltd

31 January 2014 In the Pipeline

Derek Lowe thinks the Devil's R&D management schemes might be scarily familiar

Is there a drug for that?

7 January 2014 In the Pipeline

Derek Lowe ponders whether anything is truly ‘undruggable’ if we look in the right places

Rolling boulders uphill

27 November 2013 In the Pipeline

Is Derek Lowe troubled by his failure to develop a compound that has made it to the pharmacy shelf?

Natural born chemists

31 October 2013 In the Pipeline

Redesigning nature's catalysts is tantalising but tricky, says Derek Lowe

What's the use?

25 September 2013 In the Pipeline

Not every reaction can be run in a bucket, says Derek Lowe, but there are limits to what should be classed as ‘useful’

The never-ending story

2 September 2013 In the Pipeline

Keeping up with the literature is impossible, says Derek Lowe.

Knowledge lost or time gained?

30 July 2013 In the Pipeline

Derek Lowe wonders whether we should mourn the decline of classic analytical techniques or embrace technological advances

Target acquired

2 July 2013 In the Pipeline

Knowing a drug’s exact biochemistry has never been a prerequisite for approval, says Derek Lowe, and nor should it be

Lab’s labourers lost?

2 July 2013 In the Pipeline

How long should scientists stay at the bench, asks Derek Lowe. How long is a piece of string?

Bespoke or bodged

30 April 2013 In the Pipeline

A can-do attitude and some lateral thinking can save time and money when it comes to exotic apparatus, says Derek Lowe

From lab to leader

2 April 2013 In the Pipeline

Derek Lowe asks (with some trepidation): do drug companies need scientists at the top?

New antibiotics: what's the hold up?

6 March 2013 In the Pipeline

It’s more a research problem, than a commercial one, says Derek Lowe

Name reactions: how does the label stick?

25 January 2013 In the Pipeline

Derek Lowe investigates the long running tradition of naming reactions after their inventors

Fear of the unknown

2 January 2013 In the Pipeline

How do you reconcile the need for personal safety with unfamiliar compounds, asks Derek Lowe

Full disclosure?

27 November 2012 In the Pipeline

The pharma industry should be more open with its trial data, says Derek Lowe

High finance meets big pharma?

31 October 2012 In the Pipeline

Derek Lowe examines an alternative funding model for pharmaceutical research

Under pressure

26 September 2012 In the Pipeline

There might be a better way to interview new starters, suggests Derek Lowe

Light in the lab

4 September 2012 In the Pipeline

Derek Lowe asks: Why don’t we use photochemistry more often?